Background
The 5-years overall survival (OS) for OSCC is 60%. TNM staging is group-based and it is limited in tailoring personalized therapy.
GF on primary tumor is a mature method to identify prognostic markers, but is limited by availability of surgical specimen. RF, based on techniques being already part of the diagnostic phase, is feasible in all pts, but techniques are not yet defined.
We recently defined a prognostic 48-genes signature (48-GS) in OSCC. Association and integration of GR and RF could pave the way to non-invasive assessment of prognostic models. We considered the series of OSCC pts with clinical stage III/IV from 5 European centers enrolled in the ongoing BD2Decide project.
Conclusions
We identified a prognostic model based on the 48-GS able to improve assessment of stage III/IV OSCC risk based on OS. Since significantly altered RFs mainly describe the variability of the intensity signals inside the tumor, their association with 48-GS could mirror biological differences.
Questo è uno degli articoli scientifici pubblicati da uno o più collaboratori e data scientist di synbrAIn.
Se sei interessato a saperne di più, leggi l’intero articolo qui.
